Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis

Laboratory Investigation

Volumn 95, Issue 1, 2015, Pages 65-77

  Zhang, Li ^a   Fu, Xiao Hong ^b   Yu, Yong ^a   Shui, Ruo Hong ^c   Li, Chun ^a   Zeng, Hai Ying ^a   Qiao, Yu Lei ^a   Ni, Li Yan ^d   Wang, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b Pudong Gongli Hospital   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d Shanghai Skin Disease Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 074ME; CATHEPSIN B; CATHEPSIN B INHIBITOR; CD68 ANTIGEN; CREATINE KINASE; CREATINE KINASE MM; LACTATE DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CA 074 METHYL ESTER; DIPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B; DERMATOMYOSITIS; FEMALE; GUINEA PIG; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTERSTITIAL LUNG DISEASE; LIVER FIBROSIS; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG PARENCHYMA; NICK END LABELING; NONHUMAN; POLYMYOSITIS; PROTEIN EXPRESSION; RAT; THERAPY EFFECT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; LUNG DISEASES, INTERSTITIAL; METABOLISM; PULMONARY FIBROSIS;

ANIMALS; APOPTOSIS; CATHEPSIN B; DERMATOMYOSITIS; DIPEPTIDES; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; LUNG DISEASES, INTERSTITIAL; PULMONARY FIBROSIS; RATS; UP-REGULATION;

EID: 84920065881     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.135     Document Type: Article

References (53)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.
2. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677-685.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-944.
4. Walter N, Collard HR, King Jr TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:330-338.
5. Nuovo GJ, Hagood JS, Magro CM, et al. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Modern Pathol 2011;25:416-433.
6. Yamashita M, Iwama N, Date F, et al. Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal. Hum Pathol 2009;40:1553-1563.
7. Corsini E, Giani A, Peano S, et al. Resistance to silica-induced lung fibrosis in senescent rats: role of alveolar macrophages and tumor necrosis factor-α (TNF). Mech Ageing Dev 2004;125:145-146.
8. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011;17:362-367.
9. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatmentrefractory interstitial lung disease. Respirology 2014;19:353-359.
10. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.
11. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. Arch Histol Cytol 2001;64:233-246.
12. Yang CN, Shiao YJ, Shie FS, et al. Mechanism mediating oligomeric Abeta clearance by naïve primary microglia. Neurobiol Dis 2011;42:221-230.
13. Rempel SA, Rosenblum ML, Mikkelsen T, et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 1994;54:6027-6031.
14. Krepela E, Kasafirek E, Novak K, et al. Increased cathepsin B activity in human lung tumors. Neoplasma 1990;37:61-70.
15. Sinha AA, Morgan JL, Buus RJ, et al. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients. Anticancer Res 2007;27:3135-3141.
16. Feng Y, Ni L, Wang Q. Administration of cathepsin B inhibitor CA-074Me reduces inflammation and apoptosis in polymyositis. J Dermatol Sci 2013;72:158-167.
17. Lutgens SP, Cleutjens KB, Daemen MJ, et al. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007;21:3029-3041.
18. Yan BZ, Wang M, Chen LY, et al. Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice. World J Gastroenterol 2009;15:1231-1236.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407.
21. Szapiel SV, Elsen NA, Fulmer JD, et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 1979;120:893-899.
22. Ashcroft T, Simpson JD, Timbrelli V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470.
23. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-856.
24. Altiok O, Yasumatsu R, Bingol-Karakoc G, et al. Imbalance between cysteine proteases and inhibitors in a Baboon model of bronchopulmonary dysplasia. Am J Respir Crit Care Med 2006;173:318-326.
25. Everts V, VanderZee E, Creemers L, et al. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem J 1996;28:229-245.
26. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;14:537-550.
27. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-17784.
28. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008;49:103-113.
29. Bonniaud P, Margetts PJ, Ask K, et al. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5395.
30. Kelly M, Kolb M, Bonniaud P, et al. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49.
31. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
32. Yong SJ, Adlakha A, Limper AH. Circulating transforming growth factor-beta (1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest 2001;120:68S-70S.
33. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-328.
34. Kothapalli D, Frazier KS, Welply A, et al. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor dependent signaling pathway. Cell Growth Differ 1997;8:61-68.
35. Kasabova M, Joulin-Giet A, Lecaille F, et al. Regulation of TGF-β1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystain C. J Biol Chem 2014;289:16239-16251.
36. Reed AM, Ernste F. The inflammatory milieu in idiopathic inflammatory myositis. Curr Rheumatol Rep 2009;11:295-301.
37. Wang DX, Lu X, Zu N, et al. Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis. Clin Rheumatol 2012;31:1691-1697.
38. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cellspecific immunosuppressants. Autoimmunity 2005;38:383-392.
39. Sauty A, Rochat T, Schoch OD, et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997;10:2907-2912.
40. Suzuki F, Kubota T, Miyazaki Y, et al. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 2012;14:R48.
41. Koslowski R, Knoch K, Kuhlisch E, et al. Cathepsins in bleomycininduced lung injury in rat. Eur Respir J 2003;22:427-435.
42. Martin SL, Moffitt KL, McDowell A, et al. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulm 2010;45:860-868.
43. Moffitt KL, Martin SL, Jones AM, et al. Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis. J Cyst Fibros 2014;13:63-68.
44. Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000;106: 1127-1137.
45. Sime PJ, Marr RA, Gauldie D, et al. Transfer of tumor necrosis factoralpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factorbeta1 and myofibroblasts. Am J Pathol 1998;153:825-832.
46. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987;316:379-385.
47. Zhao MQ, Stoler MH, Liu AN, et al. Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition. J Clin Invest 2000;106:R49-R58.
48. Premzl A, Turk V, Kos J. Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J Cell Biochem 2006;97:1230-1240.
49. Cho K, Yoon SY, Choi JE, et al. CA-074Me, a cathepsin B inhibitor, decreases APP accumulation and protects primary rat cortical neurons treated with okadaic acid. Neurosci Lett 2013;548:222-227.
50. Xu M, Yang L, Rong JG, et al. Inhibition of cysteine cathepsin B and L activation in astrocytes contributes to neuroprotection against cerebral ischemia via blocking the tBid-mitochondrial apoptotic signaling pathway. Glia 2014;62:855-880.
51. Moles A, Tarrats N, Fernández-Checa JC, et al. Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick Disease. J Biol Chem 2012;287: 1178-1188.
52. Moles A, Tarrats N, Fernández-Checa JC, et al. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 2009;49:1297-1307.
53. Moles A, Tarrats N, Morales A, et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 2010;177:1214-1224.